Actinium Pharmaceuticals, Inc. - ATNM
About Gravity Analytica
Recent News
- 12.12.2025 - Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
- 12.01.2025 - Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
- 11.26.2025 - 8-K - Current report
- 11.14.2025 - 10-Q - Quarterly report [Sections 13 or 15(d)]
- 11.05.2025 - ARS - Annual Report to Security Holders
- 11.05.2025 - DEF 14A - Definitive proxy statements
- 11.04.2025 - Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
- 10.27.2025 - Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- 10.24.2025 - Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
- 10.13.2025 - Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Recent Filings
- 11.26.2025 - 8-K Current report
- 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
- 11.05.2025 - ARS Annual Report to Security Holders
- 11.05.2025 - DEF 14A Other definitive proxy statements
- 08.20.2025 - 4 Statement of changes in beneficial ownership of securities
- 08.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]